Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Bio Technology General - BTGC -- Ignore unavailable to you. Want to Upgrade?

To: yosi s who wrote (1857)	6/19/1999 12:07:00 PM
From: Jim Oravetz	Read Replies (1) \| Respond to of 2028

yosi 1)yes, non healing wounds is a large target for Oxan. Certainly, BTGC is moving aggressively to expand Oxan. sales in this area. However, if this solution becomes too lucrative, this will almost certainly become a signal for generic co's. BTGC will get most of the initial profits but it may not last too long. 2)The Jap. companies will not significantly contribute $$ for several quarters. A year from now, it will be better. 3)Hep-B is not a HUGE profit drug. It will contribute, but not all that much (to propel the stock upward). IMHO, Jim